ADSC-derived exosomes inhibit myofibroblast transdifferentiation and attenuate airway stenosis via METTL3-mediated m6A modification of TLR2

Key Points

ADSC-derived exosomes significantly inhibit myofibroblast transdifferentiation, aiding airway repair.
Key evidence shows that upregulating METTL3 enhances m6A methylation, thereby downregulating TLR2.
Analysis reveals a novel epigenetic mechanism involving the PI3K-AKT pathway that regulates myofibroblast differentiation.
This insight may enable new therapeutic strategies for treating benign airway stenosis using targeted molecular interventions.

Abstract

ADSC-Exos promote airway repair by upregulating METTL3, which enhances m6A methylation of TLR2 mRNA, downregulates TLR2, and inhibits PI3K-AKT pathway activation, thereby inhibiting myofibroblast differentiation. This study reveals a novel epigenetic mechanism for the treatment of benign airway stenosis (BAS).

ADSC-derived exosomes inhibit myofibroblast transdifferentiation and attenuate airway stenosis via METTL3-mediated m6A modification of TLR2

Key Points

Abstract

Cite This Study